Although there is increasing evidence of the effectiveness of endovascular therapy for complex aortoiliac (AI) occlusive disease, it is not universally applied to TASC D lesions.
Methods:
A total of 2096 patients, 2601 limbs with AI occlusive disease, were enrolled. The lesions were categorized as TASC D (395) or TASC A-C (2206), and we compared baseline data, procedure, and follow-up result between the 2 groups.
Results:
The success rate of the procedure was significantly lower in the TASC D group (91.6% vs 99.3%, P < .01), and more procedure complications occurred in the TASC D group (11.1% vs 5.2%, P < .01). The results of a 5-year follow-up revealed no significant difference in primary patency (77.9% vs 77.1%, P = .17) and major adverse cardiovascular and limb events (MACLE; 30.5% vs 33.4%, P = .42) between the 2 groups. A multivariate analysis revealed complications and critical limb ischemia are independent predictors of MACLE in the TASC D group.
Conclusion:
The success rate of the procedure was lower in the TASC D group. Complications were more frequent in the TASC D group, and they were related to MACLE.
SelvinEErlingerTP. Prevalence of and risk factors for peripheral arterial disease in the United States: Results from the National Health and Nutrition Examination Survey, 1999–2000. Circulation. 2004;110(6):738–743.
2.
NorgrenLHiattWRDormandyJA. Inter-Society consensus for the management of peripheralarterial disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33(suppl 1):S1–S75.
3.
SaketRRRazaviMKPadidarAKeeSTSzeDYDakeMD. Novel intravascular ultrasound-guided method to create transintimal arterial communications: initial experience in peripheral occlusive disease and aortic dissection. J Endovasc Ther. 2004;110(6):274–280.
4.
SuzukiKIidaOSogaY. Longterm results of the S.M.A.R.T. Control stent for superficial femoral artery lesions, J-SMART registry. Circ J. 2011;75(4):939–944.
5.
SixtSAlawiedAKRastanA. Acute and long-term outcome of endovascular therapy for aortoiliac occlusive lesions stratified according to the TASC classification: a single-center experience. J Endovasc Ther. 2008;15(4):408–416.
6.
SixtSKrankenbergHMöhrleC. Endovascular treatment for extensive aortoiliac artery reconstruction: a single-center experience based on 1712 interventions. J Endovasc Ther. 2013;20(1):64–73.
MurphyTPAriaratnamNSCarneyWIJr. Aortoiliac insufficiency: Long-term experience with stent placement for treatment. Radiology. 2004;231(1):243–249.
9.
SogaYYokoiHUrakawaTTosakaAIwabuchiMNobuyoshiM. Long-term clinical outcome after endovascular treatment in patients with intermittent claudication due to iliofemoral artery disease. Circ J. 2010;74(8):1689–1695.
10.
BoschJLHuninkMG. Meta-analysis of the results of percutaneous transluminal angioplasty and stent placement for aortoiliac occlusive disease. Radiology. 1997;204(1):87–96.
11.
PonecDJaffMRSwischukJ; CRISP Study Investigators. The nitinol SMART stent vs Wall stent for suboptimal iliac artery angioplasty: CRISP-US Trial results. J Vasc Interv Radiol. 2004;15(9):911–918.
12.
IidaOSogaYTakaharaM. Efficacy of the S.M.A.R.T. Control vs. other stents for aortoiliac occlusive disease in contemporary clinical practice. J Endovasc Ther. 2013;20(3):431–439.
13.
JongkindVAkkersdijkGJYeungKKWisselinkW. A systematic review of endovascular treatment of extensive aortoiliac occlusive disease. J Vasc Surg. 2010;52(5):1376–1383.
14.
DormandyJARutherfordRB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 pt 2):S1–S296.
15.
European Stroke Organisation, TenderaMAboyansVBartelinkML; ESC Committee for Practice Guidelines. ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011;32(22):2851–2906.
16.
IidaOSogaYTakaharaM. Perioperative complications after aorto-iliac stenting: associated factors and impact on follow-up cardiovascular prognosis. Eur J Vasc Endovasc Surg. 2014;47(2):131–138.
17.
De VriesSHuninkM. Results of aortic bifurcation grafts for aortoiliac occlusive disease: a meta-analysis. J Vasc Surg. 1997;26(4):558–569.
18.
PassmanMATaylorLMMonetaGL. Comparison of axillofemoral and aortofemoral bypass for aortoiliac occlusive disease. J Vasc Surg. 1996;23(2):263–269.
19.
MartinDKatzSG. Axillofemoral bypass for aortoiliac occlusive disease. Am J Surg. 2000;180(2):100–103.
20.
SogaYIidaOKawasakiD; REAL-AI investigators. Contemporary outcomes after endovascular treatment for aorto-iliac artery disease. Circ J. 2012;76(11):2697–2704.
21.
HaltmayerMMuellerTHorvathWLuftCPoelzWHaidingerD. Impact of atherosclerotic risk factors on the anatomical distribution of peripheral arterial disease. Int Angiol. 2001;20(3):200–207
22.
OzkanUOguzkurtLTercanF. Atherosclerotic risk factors and segmental distribution in symptomatic peripheral artery disease. J Vasc Interv Radiol. 2009;20(4):437–441.
23.
ConteMSGeraghtyPJBradburyAW. Suggested objective performance goals and clinical trial design for evaluating catheter-based treatment of critical limb ischemia. J Vasc Surg. 2009;50(6):1462–1473.
24.
ChatterjeeSWetterslevJSharmaALichsteinEMukherjeeD. Association of Blood Transfusion With Increased Mortality in Myocardial Infarction: A Meta-analysis and Diversity-Adjusted Study Sequential Analysis. JAMA Intern Med. 2013;173(2):132–139.
